<DOC>
	<DOC>NCT00761774</DOC>
	<brief_summary>The Sponsor wishes to develop brivaracetam as an anti-epileptic treatment in subjects 16 years and older with epilepsy. This study permits continued access to treatment for subjects who participated in a previous epilepsy study. The study will explore the long-term safety and efficacy of brivaracetam.</brief_summary>
	<brief_title>An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<criteria>Subjects with epilepsy who participated in previous brivaracetam trials which allow access to the present trial. Subjects from whom the Investigator believes a reasonable potential benefit from the longterm administration of brivaracetam may be expected. â€¢ Severe medical, neurological and psychiatric disorders, including current suicidal ideation or behaviour, or laboratory values which may have an impact on the safety of the subject, as determined by the investigator.</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Epilepsy</keyword>
	<keyword>Monotherapy</keyword>
	<keyword>Partial Onset Seizures</keyword>
</DOC>